Free US stock earnings analysis and guidance reviews to understand company fundamentals and future prospects. Our earnings season coverage includes detailed analysis of financial results and what they mean for your investment thesis.
On April 21, 2026, Merck (MRK) announced that U.S. FDA granted priority review to two supplemental biologics license applications (sBLAs) for its Keytruda (both intravenous and subcutaneous formulations) in combination with Pfizer’s antibody-drug conjugate (ADC) Padcev, for the treatment of cisplati
Pfizer Inc. (PFE) – Padcev Combination Therapy Receives FDA Priority Review for Expanded Bladder Cancer Indication - Partnership
PFE - Stock Analysis
4388 Comments
809 Likes
1
Mordekai
Expert Member
2 hours ago
This feels like I’m late to something again.
👍 198
Reply
2
Cayslee
Insight Reader
5 hours ago
This would’ve helped me avoid second guessing.
👍 38
Reply
3
Anuoluwa
Influential Reader
1 day ago
Incredible energy in everything you do.
👍 220
Reply
4
Abel
Active Reader
1 day ago
Market is holding support levels, which is encouraging for trend continuation.
👍 162
Reply
5
Asyra
Active Contributor
2 days ago
Free US stock earnings trajectory analysis and revision trends to understand fundamental momentum. We track how analyst estimates have been changing over time to gauge improving or deteriorating expectations.
👍 220
Reply
© 2026 Market Analysis. All data is for informational purposes only.